Serina Therapeutics's three largest insider shareholders as of September 29, 2026 are Gregory Bailey (Director, 8.56Mn shares), Jay Venkatesan (Director, 232.29K shares), Steven Mintz (Director, 25.97K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Gregory Bailey | Director | 8,564,382 | 0 | 8,564,382 | 96.7% | 22 Jun, 2026 |
| 2 | Jay Venkatesan | Director | 589 | 231,705 | 232,294 | 2.6% | 22 Jun, 2026 |
| 3 | Steven Mintz | Director | 0 | 25,973 | 25,973 | 0.3% | 16 Sep, 2024 |
| 4 | Richard Peter Marshall | Director | 12,183 | 0 | 12,183 | 0.1% | 22 May, 2026 |
| 5 | Karen J Wilson | Director | 10,100 | 0 | 10,100 | 0.1% | 15 Jun, 2026 |
| 6 | Steven A Ledger | Chief Executive Officer | 10,100 | 0 | 10,100 | 0.1% | 27 May, 2026 |
| 7 | Michael D West | Chief Executive Officer | 1,194 | 0 | 1,194 | 0.0% | 14 Mar, 2023 |
| 8 | Stephen K. Brannan | Director | 1,000 | 0 | 1,000 | 0.0% | 09 Jul, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 22 Jul, 2026 | Farrell Simon | Director | Acquired A | 30,500 | $0.00 | $0 | 30,500 | Direct |
| 07 Jul, 2026 | Stephen K. Brannan | Director | Acquired P | 1,000 | $2.03 | $2.03K | 1,000 | Direct |
| 17 Jun, 2026 | Stephen K. Brannan | Director | Acquired A | 15,250 | $0.00 | $0 | 15,250 | Direct |
| 22 May, 2026 | Jay Venkatesan | Director | Acquired P | 589 | $1.78 | $1.05K | 589 | Direct |
| 17 Jun, 2026 | Gregory Bailey | Director | Acquired C | 1,770,805 | $2.25 | $3.98Mn | 1,897,445 | Direct |
| 17 Jun, 2026 | Richard Peter Marshall | Director | Acquired A | 15,250 | $0.00 | $0 | 15,250 | Direct |
| 17 Jun, 2026 | Jay Venkatesan | Director | Acquired C | 224,152 | $2.25 | $504.34K | 231,705 | Indirect |
| 17 Jun, 2026 | Karen J Wilson | Director | Acquired A | 15,250 | $0.00 | $0 | 15,250 | Direct |
| 17 Jun, 2026 | Gregory Bailey | Director | Acquired C | 6,666,667 | $2.25 | $15.00Mn | 8,564,382 | Direct |
| 17 Jun, 2026 | Jay Venkatesan | Director | Acquired A | 15,250 | $0.00 | $0 | 15,250 | Direct |
| 17 Jun, 2026 | Gregory Bailey | Director | Acquired A | 15,250 | $0.00 | $0 | 15,250 | Direct |
| 17 Jun, 2026 | Jay Venkatesan | Director | Disposed C | 96,525 | $2.25 | $217.18K | 0 | Indirect |
| 17 Jun, 2026 | Gregory Bailey | Director | Acquired A | 3,333,333 | $0.00 | $0 | 3,333,333 | Direct |
| 17 Jun, 2026 | Gregory Bailey | Director | Disposed C | 762,548 | $2.25 | $1.72Mn | 0 | Direct |
| 11 Jun, 2026 | Karen J Wilson | Director | Acquired P | 5,100 | $1.75 | $8.90K | 5,100 | Direct |
| 12 Jun, 2026 | Karen J Wilson | Director | Acquired P | 5,000 | $1.77 | $8.85K | 10,100 | Direct |
| 26 May, 2026 | Steven A Ledger | Chief Executive Officer | Acquired A | 10,100 | $1.93 | $19.49K | 10,100 | Direct |
| 21 May, 2026 | Randall Moreadith | Chief Scientific Officer | Acquired A | 85,558 | $0.00 | $0 | 85,558 | Direct |
| 21 May, 2026 | Srini Tenjarla | Svp, Cmc Formulation | Acquired A | 85,558 | $0.00 | $0 | 85,558 | Direct |
| 21 May, 2026 | Karen J Wilson | Director | Acquired P | 10,000 | $1.77 | $17.70K | 10,000 | Direct |